Aravive Added to the Russell 2000 and Russell 3000 Indexes
HOUSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening
diseases, including cancer and fibrosis, today announced that the Company has been added to the Russell 2000 and Russell 3000 Indexes, effective June 29, 2020, as part of the 2020 Russell U.S.
indexes reconstitution.
“Our inclusion in the Russell indexes reflects the meaningful progress we have made toward our goal of changing the treatment paradigm for people living with cancer,” said Gail McIntyre, Ph.D., chief executive officer of Aravive. “We believe our inclusion will enhance Aravive’s visibility within the investment community and have a positive impact on the liquidity of our stock.”
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on the Russell 2000 and Russell 3000 Indexes and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
Lesen Sie auch
About Aravive
Aravive, Inc. (Nasdaq: ARAV) is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis.
Aravive’s lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, AVB-500 starves the AXL pathway of its
signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays an important role in multiple types of malignancies by promoting metastasis,
cancer cell survival, resistance to treatments, and immune suppression. The GAS6-AXL signaling pathway also plays a significant role in fibrogenesis. Aravive is actively evaluating
AVB-500 in platinum-resistant ovarian cancer and clear cell renal cell carcinoma and intends to expand development into additional oncology indications. Aravive is based in Houston,
Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.